GRDX

Insider Trades

Name	Value	Action	Price	Current Price
Romano SarahChief Financial Officer $465727 shares SellJan 6, 2025 $0.64 --
Romano SarahChief Financial Officer $212476 shares SellOct 9, 2024 $0.446 --
Romano SarahChief Financial Officer $664621 shares SellJul 2, 2024 $1.07 --
Sapirstein JamesDirector, Officer: Chairman And CEO $1.4k1.3k shares SellJul 2, 2024 $1.07 --

News

newsfilecorp.comGridAI Technologies Corp. to Present at the Market Movers Investor Summitnewsfilecorp.comApr 29

newsfilecorp.comGridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filingnewsfilecorp.comApr 28

Trade GRDX

About GridAI Technologies Corp.

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

CEO: Jason David Sawyer
IPO Date: Oct 11, 2016

Market Data

Open: $5.20
High: $5.47
Low: $5.00
Volume: 170.2K
Avg Volume: 120.7K
52W High: $6.93
52W Low: $1.08

Valuation

Market Cap: $18M
Enterprise Value: $20M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-5.7M
Revenue: $36k
Net Income: $-6.4M
Cash: $900k
Debt: $2.3M

Events

EarningsAug 17

EPS est. -9450